THYROID CANCERS

Steven I. Sherman, MD, FACE, moderated a Targeted Oncology Case-Based Roundtable event during which experts discussed the characteristics of patients with radioiodine-refractory differentiated thyroid cancer and how to consider them when selecting treatment.

The FDA has granted a fast track designation to the autologous chimeric antigen receptor T-cell agent, AIC100, for the treatment of patients with anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.

Overall survival was prolonged in patients with radioactive iodine-refractory differentiated thyroid cancer and lung metastases larger than 1 cm who were treated with lenvatinib in the SELECT study.

The DECISION and SELECT studies provide evidence of response to multikinase inhibitors after disease progression in patients with thyroid carcinoma.

Vivek Subbiah, MD, discusses the updated results of the LIBRETTO-001 trial, specifically the effect of selpercatinib on RET fusion-positive thyroid tumors.

In an interview with Targeted Oncology, Vivek Subbiah, MD, reviewed the data supporting selpercatinib as treatment of RET fusion-positive thyroid cancers, as well as the exploration of this agent in other RET-altered cancers.

During a virtual Targeted Oncology Case-Based Roundtable event, Marcia S. Brose, MD, PhD, discussed the case of a 58-year-old patients with RET-mutated thyroid cancer.

During a virtual Targeted Oncology Case-Based Roundtable event, Lori Wirth, MD, discussed the treatment patients with radioiodine-refractory differentiated thyroid cancer with a group of peers.

During a virtual Targeted Oncology Case-Based Roundtable event, Bryan McIver, MD, PhD, discussed the case of a 58-year-old patient with RET-mutant medullary thyroid cancer.

Vivek Subbiah, MD, explains what sets medullary thyroid cancer apart from other thyroid cancer histologies.

During a virtual Targeted Oncology Case-Based Roundtable event, Marcia S. Brose, MD, PhD, led a peer discussion about frontline treatment of a patient with differentiated thyroid cancer.

TPX-0046, a next-generation RET inhibitor demonstrated preliminary clinical activity in patients with RET-driven cancers who were treated in the phase 1/2 SWORD-1 clinical trial.

A number of clinical trials have provided evidence of efficacy of combination regimens for the treatment of RET-mutant medullary thyroid cancer. During a virtual Targeted Oncology Case-based Roundtable event, Lori Wirth, MD, discussed the options for a 58-year-old man with RET-mutant medullary thyroid cancer.

Christine Dierks, MD, describes the prognosis of the anaplastic thyroid carcinoma and differentiated thyroid cancer populations.

In advanced medullary thyroid cancer, mortality may be predicted by serum carbohydrate antigen 19.9 (Ca19.9) positivity in patients as well as by doubling times less than 6 months and less than 1 year. Results of a retrospective study suggest that these 2 new prognostic factors should be considered when initiating treatment for patients with MTC.

The rising prevalence of thyroid cancer and thyroid nodules, especially for differentiated thyroid cancer, has brought into question the management of disease as it is known today.

The FDA has granted Breakthrough Therapy Designation to cabozantinib for the potential treatment of patients with differentiated thyroid cancer that has progressed following prior therapy and who are radioactive iodine-refractory if eligible for radioactive iodine.

Steven Sherman, MD, FACE, provides closing thoughts on unmet needs and future directions for the treatment of patients with RAI-refractory DTC.

Approaching patient education of RAI-refractory DTC therapy with lenvatinib, fostering open communication between patients and providers, and monitoring medication adherence.

An expert endocrinologist perspective on managing the toxicities associated with lenvatinib when treating RAI-refractory DTC and the role of dose reduction and interruption.

A review of a multicenter phase 2 study evaluating the safety and efficacy of lenvatinib starting doses in RAI-refractory DTC.

A review of the phase 3 SELECT trial examining the use of lenvatinib for the treatment of RAI-refractory DTC and the management of adverse events.

Steven Sherman, MD, FACE, provides an overview of the history and evolution of treating patients with RAI [radioactive iodine]–refractory differentiated thyroid cancer [DTC].

Steven Sherman, MD, FACE, provides insight on the treatment of radioactive iodine-refractory differentiated thyroid cancer and the management of adverse events.

In an interview with Targeted Oncology, Maria E. Cabanillas, MD, discussed the use of larotrectinib as treatment of patients with thyroid cancer and the pooled findings from 2 larotrectinib trials.

Gallium-68 prostate-specific membrane antigen PET imaging demonstrated the ability to detect metastatic thyroid cancer but resulted in a lower detection rate compared with 2-[18F]FDG PET for thyroid cancer lesion visualization.

Christine Dierks, MD, discusses how PD-L1 expression is used to determine treatment for patients with thyroid cancer.

Patients with tissue tumor mutational burden-high solid tumors represent a subset of patients who could have a robust tumor response to the immune checkpoint inhibitor pembrolizumab as monotherapy, suggesting tTMB may be a novel and useful predictor of response in patients with previously treated recurrent or metastatic advanced solid tumors, including thyroid cancer.

Cabozantinib demonstrated significant improvement in progression-free survival in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after up to 2 prior vascular endothelial growth factor receptor-targeted therapies compared with placebo, meeting the primary end point of the pivotal phase 3 COSMIC-311 clinical trial.

Marcia Brose, MD, PhD, discusses a global, non-interventional study that assessed the use of sorafenib as treatment of patients with asymptomatic radioiodine-refractory differentiated thyroid cancer.